| Literature DB >> 34773563 |
Mallavalli Surendranath1, Ravi Wankhedkar2, Jayesh Lele3, Otavio Cintra4, Shafi Kolhapure5, Ashish Agrawal6, Pavitra Dewda7,8.
Abstract
Healthcare providers (HCPs) are at increased risk of acquisition and transmission of infectious disease. Vaccinating HCPs is an essential preventive measure to protect them and their patients against communicable diseases, while positively and directly impacting the functioning of the healthcare system. In India, healthcare represents one of the largest employment sectors with 3.8 million HCPs; however, there is limited awareness of national immunisation guidelines for the Indian HCP population. Data from communicable disease outbreaks across India suggest inadequate vaccination rates amongst HCPs; studies have reported influenza and varicella vaccination rates as low as 4.4% and 16%, respectively. In this review, we discuss data highlighting the impact of insufficient vaccination coverage, barriers to vaccination, and the lack of immunisation guidelines amongst HCPs in India. COVID-19 vaccination programmes for HCPs have been critical in slowing the pandemic in India. This provides an opportunity to raise awareness about the importance of vaccines amongst HCPs in India.Entities:
Keywords: Healthcare providers; India; Recommendations; Vaccination
Year: 2021 PMID: 34773563 PMCID: PMC8590119 DOI: 10.1007/s40121-021-00558-9
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382
Fig. 1Number of Central Council for Indian Medicine and National Medical Commission colleges in India. aAs of 2014. Remaining data are as of 2017.
Source: Central Council of Indian Medicine 2014 estimates https://www.ccimindia.org/index.php. Accessed September 2021. 2017 Estimates of Central Bureau of Health Intelligence and National Health Profile 2018. http://www.cbhidghs.nic.in/WriteReadData/l892s/Before%20Chapter1.pdf. Accessed September 2021. The National Medical Commission has now replaced the Medical Council of India
Fig. 2HCPs receiving vaccines across centres in India. aBhatti VK, et al. Med J Armed Forces India 2014;70:220–4; bSwarnapriya K, et al. Asian Pac J Cancer Prev 2015;16:8473–7; cPandey S, et al. Indian J Med Res 2013;137:388–90; dSingh MP, et al. J Med Virol 2010;82:341–4; eAnjum FB, et al. Int J Med Res Health Sci 2016;5:115–20; fPhukan P, et al. Int J Occup Environ Med 2014;4:40–50; gPathak R, et al. Int J Med Public Health 2013;3:55–9; hKumar S, et al. International J Sci Study 2014;1:43–6; iDev K, et al. J Assoc Physicians India 2018;66:27–30; jSukriti, et al. J Gastroenterol Hepatol 2008;23:1710–5. HBV, hepatitis B virus; HCP, healthcare provider; HPV, human papillomavirus
Fig. 3Global hepatitis B and influenza vaccination coverage among HCPs. Sources: Delhi: Sukriti, et al. J Gastroenterol Hepatol 2008;23:1710–5. Mangalore: Kumar HN, et al. Ann Glob Health 2015;81:664–8. Bhopal: Singh A. J Dent Educ 2011;75:421–7. Tanzania: Aaron D. BMC Infect Dis 2017;17:786. Cameroon: NDongo CB. J Viral Hepat 2018;25:1582–7. Italy: Genovese C, et al. J Prev Med Hyg 2019;60:E12–E17. China, Croatia, France, Germany, Greece, Hungary, India, Qatar, UK (England), USA: Havairi S, et al. Hum Vaccin Immunother 2015;11:2522–37. Canada: Hussain H, et al. Influenza Other Respir Viruses 2018;12:319–25. France 2006–2007: Loulergue P, et al. Vaccine 2009;27:4240–3. HBV, hepatitis B virus; HCP, healthcare provider
Needle stick injuries among Indian HCPs
| HCPs experiencing needle stick injuries, % | ||||||
|---|---|---|---|---|---|---|
| Consultants | Residents | Interns | Staff nurses | Lab technicians | Support staff | |
| Rishi E et al. 2017a | 21 | NR | 24 | 23 | 10 | 6 |
| Swetharani et al. 2016b | NR | 67.5 | NR | 34.1 | 10 | NR |
| Rajkumari N et al. 2014c | NR | NR | NR | 14.60 | 0.30 | 8.60 |
| Sharma A et al. 2012d | NR | 27.08 | 47 | 10.10 | NR | 1.10 |
| Sharma R et al. 2010e | NR | NR | 16.20 | 21.40 | 25.60 | NR |
| Mehta A et al. 2010f | 16 | NR | NR | 44 | 9 | 23 |
| Mehta A et al. 2005 g | 11 | NR | NR | 45 | 11 | 33 |
HCP, healthcare provider; NR, not reported
aRishi E, et al. Indian J Ophthalmol 2017;65:999–1003
bSwetharani K, et al. Indian J Occup Environ Med 2016;20:138–43
cRajkumari N, et al. Injury 2014;45:1470–78
dSharma A, et al. Indian J Public Health 2012;56:101–03
eSharma R, et al. Indian J Community Med 2010;35:74–7
fMehta A, et al. Indian J Med Microbiol 2010;28:17–20
gMehta A, et al. J Hosp Infect 2005;60:368–73
Global barriers to vaccinations among HCPs
| HCPs (India)a | CHWs (India)b | HCPs (EU)c | HCPs (China)d |
|---|---|---|---|
| Too busy to get vaccinated | Required materials unavailable | Already immune | Obtained immunity from work |
| Not aware of vaccines/lack of knowledge | Lack of updated and practical information | Inconvenient vaccination timing and sites | Hospitals not providing vaccines |
| Vaccines are not available/freely available | Use of medical terminology | Fear of side effects, adjuvants or ingredients | Too busy |
| Doubts of vaccine efficacy and safety | Lack of resources to gather information | Concerns over newer vaccines | Officially not recommended |
| Fear of side effects | Lack of time | Low vaccine efficacy and effectiveness | |
| Needle phobia | Perceived low risk of contracting diseases | ||
| Cost of vaccine | |||
| Low perception of susceptilibiliy/risk/contracting disease | |||
| Disease not severe (e.g. influenza) | |||
| Egg allergy | |||
| Lack of understanding of disease/infection |
CHWs, community health workers; EU, European Union; HCP, healthcare provider
aSources: Bali NK, et al. Influenza Other Respir Viruses 2013;7:540–45; Pandey S, et al. Indian J Med Res 2013;137:388–90; Dev K, et al. J Assoc Physicians India 2018;66:27–30; Pathak R, et al. Int J Med Public Health 2013;3:55–9; Fazili AB, et al. Int J Med Res Health Sci 2016;5:115–20; Swarnapriya K, et al. Asian Pac J Cancer Prev 2015;16:8473–7
bSources: Raj S, et al. Health Info Libr J 2015;32:143–9
cSource: ECDC 2015. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/vaccine-hesitancy-among-healthcare-workers.pdf. Accessed September 2021
dSource: Yuan Q, et al. PLoS One 2019;14:e0216598
Strategies to improve vaccination uptake among HCPs
| For influenza and MMR vaccinations (UK)a | For influenza vaccination (USA)b | For influenza vaccination (India)c |
|---|---|---|
| Provide vaccinations at convenient times | Mobile carts | Regular monitoring |
| Send more reminders | Free vaccines | Incentives for vaccination |
| Provide more information on the advantages and disadvantages of vaccines | Adequate staff resources for vaccine campaign | Intensified advertising campaign |
| Advertise vaccination better | Education on the benefits and risks of immunisation | Offer choice of influenza vaccines |
| Free parking for staff at vaccination sites | Incentives for vaccination | Continuous education of HCPs |
| Introduce peer vaccination | Availability at evenings and weekends | Mandatory vaccination policy except when contraindicated |
| Availability at convenient places | Convenient access to vaccination at work | |
| Employment conditional upon receipt of vaccine |
HCP, healthcare provider; MMR, measles, mumps and rubella; UK, United Kingdom; USA, United States of America
aLittle KE, et al. Public Health 2015;129:755–62
bWeber DJ, et al. Isr J Health Policy Res 2016;5:61
cBali NK, et al. Influenza Other Respir Viruses 2013;7:540–5
Global, US and Indian recommendations for vaccinations in HCPs
| Vaccinea | WHO 2019b (Global) | CDC/ACIPc (US) | The Indian Association of Occupational Health (IOAH)d | Association of Physicians in India (API)e | Indian Medical Association (IMA)f |
|---|---|---|---|---|---|
| Hepatitis A | None | None | 2 doses (single antigen vaccine)—0 and 6–12 months 3 doses (if combined hepatitis A and B)—0, 1 and 6 months | Not recommended | 2 doses (inactivated vaccine)—0–6 months 1 dose (live vaccine) |
| Hepatitis Bg | Unvaccinated who may be exposed to blood and blood products at work | Unvaccinated/incomplete series or no vaccination history, no up-to-date immunity status 2 doses—0 and 1 month 3 doses—0, 1 and 5 months after dose 2 Anti-HBs serology 1–2 months after final dose | 3 doses—0, 1 and 6 months | 3 doses—0, 1 and 6 months | 3 doses—0, 1 and 6 months |
| MMR | Proof/documentation of immunity or immunisation should be required as a condition of enrolment into training and employment HCPs are not at risk of mumps | Born in 1957 or later with no MMR vaccination or up-to-date immune status 2 doses of MMRh (gap of 28 days) | 2 MMR doses – 4–8-week interval 1 dose if previously immunised | 2 MMR doses | 2 MMR doses—4–8-week interval |
| Meningococcal | One booster dose 3–5 years after the primary dose may be given to persons considered to be at continued risk of exposure | 1 dose for those who are routinely exposed to isolates of | 1 or 2 doses Booster every 5 years if risk remains | 1 dose—during an outbreak | 1 dose Repeat after 3–5 years if high risk |
| Influenza | Annual immunisation with a single dose is recommended | 1 dose—every year | 1 dose—every year | Not recommended | 1 dose—every year |
| Varicella | Unvaccinated and with no history of varicella infection 2 doses of varicella vaccine | No history of varicella infection or vaccination or unknown immune status 2 doses, 4 weeks apart | 2 doses—4–8-week interval 1 dose—if previously vaccinated | 2 doses—4–8-week interval | 2 doses—4–8-week interval |
| Tetanus | None | One-time Tdap dose immediately if not received earlier (despite previous Td) Td/Tdap boosters every 10 years Pregnant HCPs need Tdap in each pregnancy | 1 dose of Tdap—then Td booster every 10 years | 1 dose of Tdap—if not received Tdap vaccine before and ≥ 2 years since last Td vaccine Td booster every 10 years | 1 dose of Tdap—every 10 years |
| Diphtheria | Revaccination of HCPs with diphtheria boosters every 10 years, especially those who may have occupational exposure | ||||
| Pertussis | HCPs should be a prioritised population | ||||
| Polio | All HCPs should have completed primary doses | None | 1 or 2 doses (if unvaccinated )—0, 4–8 weeks | None | 1 or 2 doses (if unvaccinated )—0, 4–8 weeks |
| Pneumococcal | None | Not stated specifically for HCPs | PCV13 1 dose PPSV23 1 dose | Not recommended | Not stated specifically for HCPs |
| Typhoid | None | Microbiologists and others who work frequently with | 1 dose | 3 doses—for entire community during outbreaks Booster every 3 years | 1 single dose If un-conjugated vaccine give every 3 years |
| Rabies | HCPs may receive pre-exposure prophylaxis if they are regularly caring for patients with rabies | None | 3–4 doses PEP—0, 7, 21, 28 days | 3 doses PEP—0, 7, 28 days | 3 doses PEP—0, 7, 28 days (especially in veterinarians) |
| COVID-19i | HCPs should be a prioritised population | HCPs should be a prioritised population | None | None | None |
ACIP, Advisory Committee on Immunization Practices; BCG, Bacillus Calmette-Guérin; CDC, Centres for Disease Control; HBs, hepatitis B surface antibody; HCP, healthcare provider; IGRA, interferon-gamma release assay; MMR, measles, mumps and rubella; PCV13, pneumococcal conjugate vaccine; PEP, pre-exposure prophylaxis; PPSV23, pneumococcal polysaccharide vaccine; TB, tuberculosis; Td, tetanus and diphtheria; Tdap, tetanus, diphtheria and pertussis; TST, tuberculin skin test; US, United States; WHO, World Health Organization
aNo specific recommendations for HCPs for cholera and yellow fever. Only the WHO provides recommendations for BCG (TB) vaccination: In unvaccinated TST- or IGRA-negative persons at risk of occupational exposure in low and high TB incidence areas
bSource: WHO. 2020. Available from: https://www.who.int/immunization/policy/Immunization_routine_table4.pdf. Accessed September 2021 and COVID-19 specific: https://www.who.int/docs/default-source/immunization/sage/covid/sage-prioritization-roadmap-covid19-vaccines.pdf?Status=Temp&sfvrsn=bf227443_2 Accessed September 2021
cSource: CDC (and ACIP). 2021. Available from: https://www.cdc.gov/vaccines/adults/rec-vac/hcw.html and https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm Accessed September 2021 and COVID-19 specific: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/hcp.html and https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html Accessed September 2021
dSource: IAOH. 2020. Available from: http://storage.unitedwebnetwork.com/files/162/b8a89025513aba3a9c888c097e204122.pdf. Accessed September 2021
eSource: API Guidelines. 2009. Available from: https://www.japi.org/s274e444/executive-summary-the-association-of-physicians-of-india-evidence-based-clinical-practice-guidelines-on-adult-immunization. Accessed September 2021
fSource: IMA. 2018. Available from: http://www.ima-india.org/ima/pdfdata/IMA_LifeCourse_Immunization_Guide_2018_DEC21.pdf. Accessed September 2021
gPost-vaccination testing may be required after 1–2 months of last dose
hOne dose of rubella recommended, eventually two doses will be needed as standalone rubella vaccine is not available
iVaccination based on local recommendations
| Healthcare providers (HCPs) are the frontline workforce tackling infectious and vaccine-preventable diseases (VPDs) |
| With limited awareness regarding immunisation guidelines amongst HCPs in India, vaccination coverage is low |
| This can have a significant impact on the health of HCPs and patients, placing an unnecessary burden on the healthcare system |
| There are several barriers to vaccination uptake in HCPs, including a lack of awareness regarding the risk of VPDs and available vaccines |
| With effective education and implementation of immunisation programmes, vaccine uptake may increase amongst HCPs |